Painful Sex and Vaginal Dryness: What You Can Do.
Menopause, Painful Sex and Vaginal Dryness: What You Can Do
Even if you can't—or don't want to—use systemic hormone therapy, you still have options.
Hot flashes tend to get most of the attention when people talk about menopause. But for many women, the symptoms that linger—or become more noticeable with time—are much more private: vaginal dryness, burning, irritation, pain with penetration, urinary discomfort or repeated urinary tract infections.
These symptoms are part of genitourinary syndrome of menopause (GSM). As estrogen and other sex-hormone levels decline, the tissues of the vulva, vagina and lower urinary tract can become thinner, drier and less elastic. Natural lubrication may decrease. The vaginal opening can feel tight or tender. Sex that was once comfortable may begin to hurt. Some women also notice urinary urgency, burning or recurrent UTIs.
The good news is that systemic menopausal hormone therapy—pills, patches, gels or sprays that circulate throughout the body—is not the only way to treat GSM. In fact, when symptoms are mainly vaginal or urinary, treatment can often be targeted directly to those tissues.
First: "No HRT" Does Not Mean "No Treatment"
It helps to separate systemic hormone therapy from local vaginal therapy. Systemic estrogen reaches the bloodstream and tissues throughout the body and is commonly used for symptoms such as hot flashes and night sweats. Low-dose vaginal estrogen, by contrast, is placed in or around the vagina and is designed to act primarily on local tissue. ACOG distinguishes these approaches and notes that vaginal creams, tablets/inserts and rings deliver small doses directly to vaginal tissue.
That distinction matters if you have decided against systemic HRT, or if a clinician has told you systemic hormone therapy is not a good choice because of your medical history. It does not automatically mean every local vaginal treatment is off the table. Individual risks still matter, especially with a history of hormone-sensitive cancer, unexplained bleeding, blood clots or other significant medical conditions, so this is a decision to make with your clinician.
Option 1: Lubricants and Vaginal Moisturizers
For mild dryness or discomfort, over-the-counter products are often the first place to start. The two main categories—vaginal moisturizers and lubricants—do different jobs, and many women benefit from using both.
Lubricant = for sex. A lubricant reduces friction at the moment you need it. For vaginal dryness or sensitivity, a plain water-based or silicone-based product is usually the best place to start. Water-based products are easy to clean up and generally compatible with condoms and toys; silicone-based lubricants last longer and can be especially helpful when friction is a major source of pain.
Moisturizer = for everyday dryness. Vaginal moisturizers are used on a schedule—often every 2 to 3 days—rather than only during sex. Look for products specifically labeled for vaginal use. Hyaluronic acid and polycarbophil are two commonly used moisturizing ingredients.
For the vulva, keep it simple. If the dryness is mainly external, a thin layer of a bland, fragrance-free barrier such as plain petrolatum can help protect the skin. Products made for the vagina are not automatically appropriate for the vulva, and ordinary scented body lotions should not be used internally.
What about coconut oil? Plain coconut oil is sometimes recommended by clinicians as an external emollient or oil-based lubricant, and some women find it comfortable. But it is not a first-choice recommendation for everyone: oil can irritate some people and can damage latex and polyisoprene condoms. If barrier contraception or STI protection is relevant, choose a water- or silicone-based lubricant that the manufacturer states is condom-compatible.
A simple starter routine: Use a vaginal moisturizer consistently every 2 to 3 days (or according to package directions), and use a generous amount of lubricant whenever you have penetrative sex. If sex still hurts despite adequate lubrication, or dryness, burning or bleeding persists, it's time to look beyond OTC products and be evaluated for GSM or another cause of pain.
How to Shop the Label
Product names below are examples, not endorsements. Formulas can change, so check the current package. For sensitive menopausal tissue, a short ingredient list, no fragrance or flavor, and a formulation designed for vaginal use are sensible priorities.
Ingredients worth looking for: hyaluronic acid and polycarbophil in moisturizers; water, plant-cellulose thickeners or silicone ingredients such as dimethicone in lubricants; and products that are fragrance-free and unflavored. For water-based lubricants, the World Health Organization recommends an osmolality below 1,200 mOsm/kg and a pH generally in the 4.0 to 7.0 range; not every retail product publishes these numbers.
What to avoid or use cautiously: fragrances, flavors, warming/cooling additives and spermicides such as nonoxynol-9 if the goal is simply lubrication. High concentrations of glycerin or propylene glycol can make a water-based lubricant hyperosmolar—that's different from saying every product containing glycerin is harmful. If a product stings, burns or seems to trigger recurrent irritation, stop using it and try a simpler formulation.
Option 2: Low-Dose Vaginal Estrogen
Low-dose vaginal estrogen is one of the most established treatments for GSM. It comes in several forms, including estradiol or conjugated-estrogen creams, vaginal tablets or inserts, and low-dose vaginal rings. The goal is to restore moisture, thickness and elasticity to estrogen-deprived tissue while keeping systemic exposure low.
It can be especially useful when the main complaints are vaginal dryness, burning, irritation, pain with sex or urinary symptoms. Cream has one practical advantage: depending on the prescribed product and instructions, it can be placed internally and can also be used at the vaginal opening when symptoms are concentrated there. Tablets, inserts and rings may be less messy and easier for some people to use consistently.
Vaginal estrogen also deserves special attention for recurrent UTIs. The American Urological Association's 2025 recurrent UTI guideline recommends vaginal estrogen for peri- and postmenopausal women with recurrent UTIs when there is no contraindication, specifically to reduce the risk of future infections.
Option 3: Intrarosa (Prasterone/DHEA)
Intrarosa is a prescription vaginal insert containing prasterone, also known as DHEA. It is FDA-approved for moderate-to-severe painful intercourse (dyspareunia) related to menopausal vulvar and vaginal atrophy. The usual FDA-labeled dose is one 6.5-mg vaginal insert daily at bedtime.
Prasterone is sometimes described as a "non-estrogen" option because the medication itself is DHEA rather than estradiol. But that description needs context: vaginal cells convert DHEA into active sex-hormone metabolites, including estrogens and androgens. Intrarosa is therefore different from estradiol cream, but it is not hormonally inert.
For painful sex and vaginal tissue changes, prasterone can be an effective alternative when vaginal estrogen is not preferred or has not worked well. Its evidence for preventing recurrent UTIs, however, is not comparable to the evidence supporting vaginal estrogen.
Option 4: Ospemifene (Osphena)
Ospemifene is a once-daily oral selective estrogen receptor modulator (SERM). It is FDA-approved to treat moderate-to-severe painful intercourse and moderate-to-severe vaginal dryness due to menopause. Unlike a vaginal cream or insert, it is taken by mouth and has tissue-selective estrogen-like effects.
Because it is systemic and has its own contraindications and warnings—including considerations related to blood clots, stroke and endometrial effects—it is not simply a "risk-free nonhormonal pill." But it can be useful for women who prefer an oral treatment or cannot comfortably use vaginal products.
Option 5: Pelvic-Floor Physical Therapy—and Looking Beyond Dryness
Not every case of painful sex after menopause is caused only by dry tissue. Pain can lead to involuntary tightening of the pelvic-floor muscles, and sometimes pelvic-floor dysfunction is present from the beginning. Pelvic-floor physical therapy can be helpful when penetration feels tight, muscles spasm, or pain continues even after dryness improves. Vaginal dilators may sometimes be used under professional guidance.
Persistent pain also deserves an examination because vulvodynia, lichen sclerosus and other skin disorders, infections and pelvic conditions can mimic or coexist with GSM. New bleeding after menopause, bleeding after sex, a new vulvar lesion, unusual discharge or persistent unexplained pain should not simply be assumed to be "normal menopause."
Which Option Fits Which Symptom?
This is a simplified guide, not a treatment ranking. Individual suitability depends on medical history, medications, symptom severity and personal preference.
| Main Symptom | Reasonable Starting Point |
|---|---|
| Mild vaginal or vulvar dryness | Vaginal moisturizer (routine use) + lubricant (during sex) |
| Persistent dryness, burning, irritation | Low-dose vaginal estrogen |
| Recurrent UTIs (peri-/postmenopausal) | Low-dose vaginal estrogen |
| Moderate-to-severe painful intercourse | Vaginal estrogen, prasterone (Intrarosa), or ospemifene (Osphena) |
| Preference for a non-vaginal, oral option | Ospemifene (Osphena) |
| Pain with tight or spasming pelvic muscles | Pelvic-floor physical therapy |
| New bleeding, lesions or unexplained pain | Prompt clinical evaluation—not self-treatment |
What About Low Libido?
Low desire deserves its own conversation. Vaginal dryness and painful sex can absolutely suppress interest in sex: if intercourse hurts, the brain quickly learns to anticipate pain rather than pleasure. Treating GSM may therefore improve sexual comfort, confidence and willingness to be intimate.
But vaginal estrogen, prasterone and ospemifene should not be presented as direct treatments for low libido. Desire is influenced by many factors, including relationship context, stress, sleep, mood, medications, body image, pain and hormonal changes. If desire remains distressingly low after pain and dryness are addressed, ask specifically about evaluation for sexual-interest/arousal concerns rather than assuming a vaginal medication should solve it.
A Simple Way to Start the Conversation
You do not have to know which medication you want before you make an appointment. A useful way to describe the problem is:
"Since menopause I've developed vaginal dryness and pain with sex, and I want to know my options without systemic HRT."
If you have urinary symptoms or recurrent UTIs, mention those too.
Then ask what is driving the symptoms and which treatment best matches the problem:
- For mild dryness, a consistent moisturizer plus lubricant may be enough.
- For persistent tissue changes or urinary symptoms, low-dose vaginal estrogen may make more sense.
- For moderate-to-severe painful intercourse, prasterone or ospemifene may be reasonable alternatives.
- If muscle tightness or pain persists, pelvic-floor therapy or further evaluation may be needed.
The Bottom Line
Painful sex and vaginal dryness are common after menopause, but they are not symptoms you simply have to tolerate. And choosing not to use systemic HRT does not leave you without meaningful options. Treatment can be as simple as the right lubricant or moisturizer—or as targeted as a low-dose vaginal medication.
The most useful question is not "Do I take hormones or not?" It is "What is causing my symptoms, and which treatment gives me the best balance of relief, convenience and risk for my situation?" That opens the door to a much more personalized—and usually much more hopeful—conversation.
Sources & Further Reading
- ACOG. The Menopause Years — vaginal moisturizers and lubricants guidance. acog.org
- ACOG. Vulvovaginal Health. Reviewed/updated 2026. acog.org
- ACOG. Experiencing Vaginal Dryness? Here's What You Need to Know. Reviewed April 2026. acog.org
- ACOG. Can I use topical estrogen long-term for vaginal dryness and painful sex? November 2025. acog.org
- ACOG. Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer.Clinical Consensus, December 2021. acog.org
- American Urological Association (AUA/CUA/SUFU). Recurrent Uncomplicated Urinary Tract Infections in Women Guideline, amended 2025. auanet.org
- U.S. FDA. Intrarosa (prasterone) prescribing information. accessdata.fda.gov
- U.S. FDA. Osphena (ospemifene) prescribing information. accessdata.fda.gov
- U.S. FDA. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026. fda.gov
- World Health Organization/UNFPA. Specifications for personal lubricants (TRS 1067, Annex 6), June 2026. who.int
- CDC. How to Use a Condom. Updated April 2024. Notes that nonoxynol-9 may irritate and oil-based products can damage latex condoms. cdc.gov
Current manufacturer ingredient information consulted for illustrative examples: Replens Long-Lasting Vaginal Moisturizer; Bonafide Revaree; AH! YES VM; Sliquid H2O; Good Clean Love BioNude; and Überlube. Product formulations and compatibility statements can change.
Medical disclaimer: This article is for general educational purposes and is not a substitute for individualized medical advice, diagnosis or treatment. Medication risks and suitability vary by person. Discuss persistent symptoms and treatment choices with a qualified health professional.
